№ lp_2_1_32691
File format: docx Character count: 37684 File size: 115 KB
Analysis of predicted versus actual patient utilisation and prescription data for tolvaptan in adults with ADPKD based on PBS records.
Year: 2021
Region: Australia
Topic: Pharmacology / Drug utilisation
Document type: Report
Organization: Drug Utilisation Sub-Committee (DUSC), Department of Health, Services Australia
Drug: Tolvaptan
Condition: Autosomal dominant polycystic kidney disease (ADPKD)
Population: Adults with chronic kidney disease stage 1–3
Data source: Pharmaceutical Benefits Scheme (PBS) database
Date of PBS listing: 1 January 2019
Treatment criteria: Nephrologist management, eGFR 30–89 mL/min/1.73m², evidence of rapidly progressing disease
Monitoring requirements: Liver function tests prior to initiation, monthly for 18 months, then every 3 months
Dosage forms: 15 mg, 30 mg, 45 mg, 60 mg, 90 mg tablets in split-dose regimens
Analysis period: First and second year of PBS listing
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Request for Coverage of Autosomal Dominant Polycystic Kidney Disease Testing
Note: Year
Topic: Medical Necessity for Genetic Testing
Document Type: Letter
Target Audience: Medical Director
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts & Leukoencephalopathy (CADASIL)
Note: Year
Theme: Neurology, Genetics
Document Type: Medical Report
Target Audience: Medical Professionals, Researchers
Contextual Description: A medical report describing the diagnosis, clinical features, and specimen requirements for the genetic condition CADASIL.
Cox2 Inhibition Ameliorates Seizure Susceptibility in a Mouse Model of Autosomal Dominant Lateral Temporal Epilepsy
Year: 2021
Region / City: Zhejiang Province, China
Topic: Epilepsy, Neuroscience
Document Type: Research Article
Organization / Institution: Zhejiang University
Author: Lin Zhou, Liang Zhou, Li-Da Su, Sheng-Long Cao, Ya-Jun Xie, Ying Shen
Target Audience: Researchers in neuroscience and epilepsy
Period of Action: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Request for Coverage of Autosomal Dominant Polycystic Kidney Disease Testing
Note: Year
Topic: Medical Necessity for Genetic Testing
Document Type: Letter
Target Audience: Medical Director
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts & Leukoencephalopathy (CADASIL)
Note: Year
Theme: Neurology, Genetics
Document Type: Medical Report
Target Audience: Medical Professionals, Researchers
Contextual Description: A medical report describing the diagnosis, clinical features, and specimen requirements for the genetic condition CADASIL.
Cox2 Inhibition Ameliorates Seizure Susceptibility in a Mouse Model of Autosomal Dominant Lateral Temporal Epilepsy
Year: 2021
Region / City: Zhejiang Province, China
Topic: Epilepsy, Neuroscience
Document Type: Research Article
Organization / Institution: Zhejiang University
Author: Lin Zhou, Liang Zhou, Li-Da Su, Sheng-Long Cao, Ya-Jun Xie, Ying Shen
Target Audience: Researchers in neuroscience and epilepsy
Period of Action: Not specified
Approval Date: Not specified
Date of Changes: Not specified
Dominant Pied
Year: 2023
Region / City: United Kingdom / Australia
Topic: Bird breeding genetics
Document type: Article
Organization / Institution: N/A
Target Audience: Bird breeders, fanciers
Period of Validity: N/A
Approval Date: N/A
Modification Date: N/A
Notice and Order Regarding Proposed Modifications to Service Performance Measurement Plan for Market Dominant Products, June 3, 2025
Year: 2025
Country: United States
Type of Document: Regulatory order
Issuing Authority: Postal Regulatory Commission
Subject: Service Performance Measurement Plan revisions
Dockets: RM2024-9, PI2025-5
Implementation Phases: Phase 1 – July 1, 2025; Phase 2 – September 1, 2025
Methods: Cluster sampling, 5-Digit ZIP Code level measurement
Relevant Documents: SPM Plan, design documents, library references
Target Audience: Postal Service management and stakeholders
Previous Related Dockets: N2024-1, PI2025-2
Content Focus: Statistical measurement and operational changes in postal services
Topics: Tolvaptan autosomal dominant